Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Worldquant Millennium Advisors LLC

Worldquant Millennium Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 156.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 150,191 shares of the biopharmaceutical company's stock after buying an additional 91,671 shares during the period. Worldquant Millennium Advisors LLC owned 0.12% of Alnylam Pharmaceuticals worth $35,341,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Larson Financial Group LLC lifted its position in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 73 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $33,000. OFI Invest Asset Management acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $35,000. Colonial Trust Co SC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $35,000. Finally, IFP Advisors Inc grew its holdings in shares of Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 47 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ALNY has been the subject of a number of analyst reports. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Needham & Company LLC reiterated a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. Citigroup lifted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research report on Friday, March 21st. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $280.00 to $328.00 in a report on Monday, March 24th. Finally, Scotiabank upped their target price on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $319.17.

Alnylam Pharmaceuticals Stock Up 0.3%

Alnylam Pharmaceuticals stock traded up $0.96 during trading on Friday, reaching $289.96. The stock had a trading volume of 757,018 shares, compared to its average volume of 917,014. Alnylam Pharmaceuticals, Inc. has a 52-week low of $146.79 and a 52-week high of $304.39. The business has a 50 day moving average price of $258.36 and a 200 day moving average price of $254.44. The stock has a market cap of $37.81 billion, a PE ratio of -133.62 and a beta of 0.17. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. Alnylam Pharmaceuticals's revenue was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.16) earnings per share. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.